These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12723729)

  • 1. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S; Burmester GR
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
    Langer HE; Missler-Karger B
    Int J Clin Pharmacol Res; 2003; 23(4):119-28. PubMed ID: 15224501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the safety of anakinra in patients with rheumatoid arthritis.
    Fleischmann RM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii29-35. PubMed ID: 12817093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A; Perniok A
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra (Kineret) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2002 Feb; 44(1124):18-9. PubMed ID: 11856953
    [No Abstract]   [Full Text] [Related]  

  • 11. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bringing the clinical experience with anakinra to the patient.
    Cohen SB; Rubbert A
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anakinra in the treatment of rheumatoid arthritis].
    Loft AG; Tarp U; Thomsen BS
    Ugeskr Laeger; 2003 Sep; 165(39):3720-4. PubMed ID: 14558384
    [No Abstract]   [Full Text] [Related]  

  • 14. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anakinra for therapy of rheumatoid arthritis].
    Tomoo T; Sumida T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
    Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
    Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.